Another example of tumor cell-targeted delivery of CRISPR/Cas9 by aptamers came from the study of Liang et al., who screened an osteosarcoma (OS) cell-specific aptamer (LC09) and constructed CRISPR/Cas9 plasmids encoding VEGFA gRNA and Cas9. This evidence concerns the gene VEGFA and neoplasm.